Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression.
Antinori A, Cossu MV, Menzaghi B, Sterrantino G, Squillace N, Di Cristo V, Cattelan A, Focà E, Castagna A, Orofino G, Valenti D, D'Ettore G, Aprea L, Ferrara S, Locatelli ME, Madeddu G, Pontali E, Scerbo P, Rossetti B, Uglietti A, Termini R, Rucci F, Gori A, Mancusi D. Antinori A, et al. Among authors: termini r. Patient. 2020 Jun;13(3):375-387. doi: 10.1007/s40271-020-00413-y. Patient. 2020. PMID: 32266663 Free PMC article.
Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
Guaraldi G, Zona S, Cossarizza A, Vernacotola L, Carli F, Lattanzi A, Nardini G, Orlando G, Garlassi E, Termini R, Garau M. Guaraldi G, et al. Among authors: termini r. Int J STD AIDS. 2014 Mar;25(3):207-12. doi: 10.1177/0956462413497701. Epub 2013 Aug 28. Int J STD AIDS. 2014. PMID: 24216034 Clinical Trial.
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
Tincati C, Savoldi A, Cannizzo ES, Bellistrì GM, Termini R, Garau M, Mancusi D, d'Arminio Monforte A, Marchetti G. Tincati C, et al. Among authors: termini r. Antivir Ther. 2016;21(2):133-42. doi: 10.3851/IMP2990. Epub 2015 Sep 10. Antivir Ther. 2016. PMID: 26355423
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
Antinori A, Meraviglia P, Monforte Ad, Castagna A, Mussini C, Bini T, Gianotti N, Rusconi S, Colella E, Airoldi G, Mancusi D, Termini R. Antinori A, et al. Among authors: termini r. Drug Des Devel Ther. 2016 May 6;10:1589-603. doi: 10.2147/DDDT.S104875. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27226708 Free PMC article.
Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy.
Codecasa LR, Toumi M, D'Ausilio A, Aiello A, Damele F, Termini R, Uglietti A, Hettle R, Graziano G, De Lorenzo S. Codecasa LR, et al. Among authors: termini r. J Mark Access Health Policy. 2017 Feb 17;5(1):1283105. doi: 10.1080/20016689.2017.1283105. eCollection 2017. J Mark Access Health Policy. 2017. PMID: 28265350 Free PMC article.
Cardiovascular disease in women with HIV-1 infection.
Volpe M, Uglietti A, Castagna A, Mussini C, Marchetti G, Bellagamba R, Bini T, Mancusi D, Termini R. Volpe M, et al. Among authors: termini r. Int J Cardiol. 2017 Aug 15;241:50-56. doi: 10.1016/j.ijcard.2017.02.117. Epub 2017 Feb 27. Int J Cardiol. 2017. PMID: 28285796 Free article. Review.
51 results